Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;189(5):815-825.
doi: 10.1111/bjh.16456. Epub 2020 Mar 5.

Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia

Eleni E Ladikou  1   2 , Timothy Chevassut  1   2 , Chris J Pepper  1 , Andrea Gs Pepper  1
Affiliations
Review

Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia

Eleni E Ladikou et al. Br J Haematol. 2020 Jun.

Abstract

Acute myeloid leukaemia (AML) is the most common adult acute leukaemia with the lowest survival rate. It is characterised by a build-up of immature myeloid cells anchored in the protective niche of the bone marrow (BM) microenvironment. The CXCL12/CXCR4 axis is central to the pathogenesis of AML as it has fundamental control over AML cell adhesion into the protective BM niche, adaptation to the hypoxic environment, cellular migration and survival. High levels of CXCR4 expression are associated with poor relapse-free and overall survival. The CXCR4 ligand, CXCL12 (SDF-1), is expressed by multiple cells types in the BM, facilitating the adhesion and survival of the malignant clone. Blocking the CXCL12/CXCR4 axis is an attractive therapeutic strategy providing a 'multi-hit' therapy that both prevents essential survival signals and releases the AML cells from the BM into the circulation. Once out of the protective niche of the BM they would be more susceptible to destruction by conventional chemotherapeutic drugs. In this review, we disentangle the diverse roles of the CXCL12/CXCR4 axis in AML. We then describe multiple CXCR4 inhibitors, including small molecules, peptides, or monoclonal antibodies, which have been developed to date and their progress in pre-clinical and clinical trials. Finally, the review leads us to the conclusion that there is a need for further investigation into the development of a 'multi-hit' therapy that targets several signalling pathways related to AML cell adhesion and maintenance in the BM.

Keywords: CXCL12/CXCR4; acute myeloid leukaemia; cell adhesion.

PubMed Disclaimer

References

    1. Abraham, M., Klein, S., Bulvik, B., Wald, H., Weiss, I.D., Olam, D., Weiss, L., Beider, K., Eizenberg, O., Wald, O., Galun, E., Avigdor, A., Benjamini, O., Nagler, A., Pereg, Y., Tavor, S. & Peled, A. (2017a) The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia, 31, 2336-2346.
    1. Abraham, M., Pereg, Y., Bulvik, B., Klein, S., Mishalian, I., Wald, H., Eizenberg, O., Beider, K., Nagler, A., Golan, R., Vainstein, A., Aharon, A., Galun, E., Caraco, Y., Or, R. & Peled, A. (2017b) Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34(+) cells in healthy volunteers. Clinical Cancer Research, 23, 6790-6801.
    1. Aiuti, A., Webb, I.J., Bleul, C., Springer, T. & Gutierrez-Ramos, J.C. (1997) The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. Journal of Experimental Medicine, 185, 111-120.
    1. Aiuti, A., Turchetto, L., Cota, M., Cipponi, A., Brambilla, A., Arcelloni, C., Paroni, R., Vicenzi, E., Bordignon, C. & Poli, G. (1999) Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. Blood, 94, 62-73.
    1. Avigdor, A., Goichberg, P., Shivtiel, S., Dar, A., Peled, A., Samira, S., Kollet, O., Hershkoviz, R., Alon, R., Hardan, I., Ben-Hur, H., Naor, D., Nagler, A. & Lapidot, T. (2004) CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood, 103, 2981-2989.

Publication types

MeSH terms